Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

被引：20

作者：

Zhang, Jinfeng ^{[1
,2
]}

Yan, Wenzhong ^{[1
]}

Duan, Wenwen ^{[1
]}

Wuthrich, Kurt ^{[1
,3
]}

Cheng, Jianjun ^{[1
]}

机构：

[1] ShanghaiTech Univ, IHuman Inst, Shanghai 201210, Peoples R China

[2] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China

[3] Scripps Res, Dept Integrated Struct & Computat Biol, La Jolla, CA 92037 USA

来源：

PHARMACEUTICALS | 2020年 / 13卷 / 09期

关键词：

GPCR; immuno-oncology; Parkinson's disease; drug binding modes; cancer therapy; PARKINSONS-DISEASE; CRYSTAL-STRUCTURE; DERIVATIVES; ZM241385; POTENT; ZM-241385; BLOCKADE; BINDING; CELLS;

D O I：

10.3390/ph13090237

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The A(2A) adenosine receptor (A(2A) AR) plays critical roles in human physiology and pathophysiology, which makes it an important drug target. Previous drug-discovery efforts targeting the A(2A) AR have been focused on the use of A(2A) AR antagonists for the treatment of Parkinson's disease. More recently, the A(2A) AR has attracted additional attention for its roles in immuno-oncology, and a number of A(2A) AR antagonists are currently used as lead compounds for antitumor drugs in both preclinical models and clinical trials. This review surveys recent advances in the development of A(2A) AR antagonists for cancer immunotherapy. The therapeutic potential of representative A(2A) AR antagonists is discussed based on both animal efficacy studies and clinical data.

引用

页码：1 / 14

页数：14

共 50 条

[1] Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Yu, Fazhi
Zhu, Chenyu
Xie, Qiong
Wang, Yonghui
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (21) : 12196 - 12212
[2] Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
Waickman, Adam T.
Alme, Angela
Senaldi, Liana
Zarek, Paul E.
Horton, Maureen
Powell, Jonathan D.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (06) : 917 - 926
[3] Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
Adam T. Waickman
Angela Alme
Liana Senaldi
Paul E. Zarek
Maureen Horton
Jonathan D. Powell
Cancer Immunology, Immunotherapy, 2012, 61 : 917 - 926
[4] Selective adenosine A2A receptor antagonists
Ongini, E
Monopoli, A
Cacciari, B
Baraldi, PG
FARMACO, 2001, 56 (1-2): : 87 - 90
[5] A2A Adenosine Receptor Antagonists in Neurodegenerative Diseases
Merighi, Stefania
Borea, Pier A.
Varani, Katia
Vincenzi, Fabrizio
Jacobson, Kenneth A.
Gessi, Stefania
CURRENT MEDICINAL CHEMISTRY, 2022, 29 (24) : 4138 - 4151
[6] Medicinal chemistry of A2A adenosine receptor antagonists
Caceiari, B
Pastorin, G
Spalluto, G
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (04) : 403 - 411
[7] Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy
Galezowski, Michal
Wegrzyn, Paulina
Bobowska, Aneta
Commandeur, Claude
Dziedzic, Katarzyna
Nowogrodzki, Marcin
Obara, Alicja
Szeremeta-Spisak, Joanna
Dzielak, Anna
Lozinska, Iwona
Dudek, Marcelina
Janiga, Anita
Reus, Jacek
Wronowski, Marek
Swirski, Mateusz
Radzimierski, Adam
Ziembik, Magdalena
Mierzwicka, Joanna
Wojcik-Jaszczynska, Katarzyna
Gocek, Elzbieta
Grycuk, Karolina
Golas, Aniela
Pierzchala, Olga
Zachmann, Julian
Nowak, Mateusz
CANCER RESEARCH, 2018, 78 (13)
[8] Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew
Strohbehn, Garth W.
Ratain, Mark J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (03) : 498 - 500
[9] Polysubstituted adenines as human adenosine A2A receptor antagonists
Dal Ben, Diego
Kachare, Dhuldeo D.
Lambertucci, Catia
Lammi, Carmen
Marucci, Gabriella
Volpini, Rosaria
Klotz, Karl-Norbert
Cristalli, Gloria
PURINERGIC SIGNALLING, 2008, 4 : S15 - S16
[10] Pharmacophore modeling of human adenosine receptor A2A antagonists
Xu, Zhejun
Cheng, Feixiong
Da, Chenxiao
Liu, Guixia
Tang, Yun
JOURNAL OF MOLECULAR MODELING, 2010, 16 (12) : 1867 - 1876

← 1 2 3 4 5 →